Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

MultiCenter, Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study of ATX-101 (Sodium Deoxycholate Injection) Versus Placebo for the Reduction of Localized Subcutaneous Fat in the Submental Area

Trial Profile

MultiCenter, Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study of ATX-101 (Sodium Deoxycholate Injection) Versus Placebo for the Reduction of Localized Subcutaneous Fat in the Submental Area

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 11 Oct 2018

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Deoxycholic acid (Primary)
  • Indications Subcutaneous fat disorders
  • Focus Registrational; Therapeutic Use
  • Acronyms REFINE-1
  • Sponsors Kythera Biopharmaceuticals
  • Most Recent Events

    • 11 Oct 2018 According to an Allergan media release, data from this study will be presented at the 2018 American Society For Dermatologic Surgery Meeting.
    • 01 Jul 2016 According to an Allergan media release, the company has received positive opinion from the Swedish Medical Products Agency (MPA) for deoxycholic acid (BELKYRA) through European decentralised procedure for the treatment of subdermal fullness.
    • 08 Mar 2016 Results of a pooled post-hoc analysis from REFINE-1 and REFINE-2 trials presented at the 74th Annual Meeting of the American Academy of Dermatology
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top